WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Life Sciences

Open PDF
  • One of the Largest Life Sciences Practices in the U.S.

    Wilson Sonsini's Life Sciences practice is one of the largest in the U.S., with more than 275 professionals, including attorneys, patent agents, and scientific advisors.

     

  • Our Attorneys Act as Strategic General Counsel, Advising on a Comprehensive Scope of Business Operations and Issues

    Wilson Sonsini's attorneys often act as strategic general counsel, drawing from their broader scope of experience and advising on matters beyond patents and IP. 

  • A Nationally Recognized and Ranked Life Sciences Practice

    Recognized as a “Leading Firm” for Life Sciences—in Nationwide, California, and Massachusetts categories—in the 2025 edition of Chambers USA: America’s Leading Lawyers for Business. The firm was also named a finalist in two “Firm of the Year” categories: Corporate Firm of the Year and Hatch-Waxman Litigation Firm of the Year (Generic) of the LMG Life Sciences 2024 Americas Awards.

A Legacy of Life Sciences Leadership

The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.

Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.

Wilson Sonsini’s Life Sciences practice is anchored by a diverse team of attorneys, patent agents, and scientific advisors, more than 100 of whom hold Ph.D.s and have significant industry experience. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).

Key Points About Our Practice

On behalf of our life sciences clients, Wilson Sonsini:

  • Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
  • Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
  • Raised 1,500+ venture rounds totaling over $38.1 billion
  • Counseled hundreds of life sciences companies on structuring strategic commercial collaborations

Our Nexus to Life Sciences Innovation

For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:

  • Agricultural biotechnology
  • Adoptive cell therapy
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genomic editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • TechBio
  • Therapeutics
  • Tissue engineering
  • Virology

Our Inter-Disciplinary Team and Comprehensive Scope of Practice

Our work with life sciences companies to help them develop and implement their business strategies encompasses:

  • Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
  • Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
  • Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
  • FDA Regulatory, Healthcare, and Consumer Products – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
  • Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
  • Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Overview

A Legacy of Life Sciences Leadership

The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.

Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.

Wilson Sonsini’s Life Sciences practice is anchored by a diverse team of attorneys, patent agents, and scientific advisors, more than 100 of whom hold Ph.D.s and have significant industry experience. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).

Key Points About Our Practice

On behalf of our life sciences clients, Wilson Sonsini:

  • Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
  • Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
  • Raised 1,500+ venture rounds totaling over $38.1 billion
  • Counseled hundreds of life sciences companies on structuring strategic commercial collaborations

Our Nexus to Life Sciences Innovation

For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:

  • Agricultural biotechnology
  • Adoptive cell therapy
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genomic editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • TechBio
  • Therapeutics
  • Tissue engineering
  • Virology

Our Inter-Disciplinary Team and Comprehensive Scope of Practice

Our work with life sciences companies to help them develop and implement their business strategies encompasses:

  • Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
  • Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
  • Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
  • FDA Regulatory, Healthcare, and Consumer Products – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
  • Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
  • Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Client Highlights
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
News Articles
Nellie Brutocao and Ben Capps Named Among SDBJ's Under 40
On June 8, 2026, Wilson Sonsini partners Nellie Brutocao and Ben Capps were honored among San Diego Business Journal’s “40 Next Top Business Leaders Under 40.” The special supplement recognizes young professionals for their achievements and community involvement in the region.
Podcasts
NextGen VC Podcast – The $2.25 Billion Exit That Changed Lumira’s Investment Strategy: Suman Rao of Lumira Ventures
In the latest episode of the NextGen VC Podcast, Suman Rao, Ph.D., principal at Lumira Ventures, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss her path from academic science to healthcare venture capital and why she believes the best investors lead with mission before money.
View All
Insights
Client Highlights
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
Client Highlights
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
News Articles
Nellie Brutocao and Ben Capps Named Among SDBJ's Under 40
On June 8, 2026, Wilson Sonsini partners Nellie Brutocao and Ben Capps were honored among San Diego Business Journal’s “40 Next Top Business Leaders Under 40.” The special supplement recognizes young professionals for their achievements and community involvement in the region.
Podcasts
NextGen VC Podcast – The $2.25 Billion Exit That Changed Lumira’s Investment Strategy: Suman Rao of Lumira Ventures
In the latest episode of the NextGen VC Podcast, Suman Rao, Ph.D., principal at Lumira Ventures, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss her path from academic science to healthcare venture capital and why she believes the best investors lead with mission before money.
View All
Affiliated Programs
MedtechASCEND Boardroom Pathways, Boards Demystified: The What, Who and Why of Your Responsibilities as a Director
Wilson Sonsini is proud to partner with MedTech Women.
Affiliated Programs
Frontiers of Neuro
Wilson Sonsini is excited to sponsor an afternoon of networking and breakthrough presentations on the frontier of neuroscience, hosted by PsyMed Ventures and E11 Bio.
Affiliated Programs
Power of Single-Cell-Multi-Omics: From Bench to Bedside
Wilson Sonsini is pleased to support EPPIC Global.
Affiliated Programs
Yokohama LINK-J Life Science Lounge NYC Meetup 2026: Bridging the U.S. and Japan Life Science Ecosystems
Wilson Sonsini is pleased to host the Yokohama LINK-J Life Science Lounge NYC Meetup 2026 – Bridging the U.S. and Japan Life Science Ecosystems. The Yokohama LINK-J Life Science Lounge is a hub established in New York through the collaboration between the City of Yokohama Representative Office to the Americas and LINK-J, with the aim of strengthening connections and fostering collaboration in the life science sector between the United States and Japan. The Lounge serves both as an information platform providing insights into the U.S. life science and business landscape, and as a networking hub that connects companies, research institutions, and industry experts, thereby promoting cross-border ecosystem collaboration and open innovation.
Affiliated Programs
CBSA Thought Leadership Series: Intellectual Property
Wilson Sonsini is proud to sponsor the Colorado Bioscience Thought Leadership Series, a forum dedicated to exploring the critical strategic issues facing today’s life sciences companies.
Affiliated Programs
MassBio Drive Fall 2026
Wilson Sonsini is proud to partner with MassBio to help empower the next generation of tech bio innovators through Drive. This accelerator equips early-stage companies with the business curriculum, mentorship, and industry connections needed to help breakthrough science move faster and further. 
View All
Events
Affiliated Programs
MedtechASCEND Boardroom Pathways, Boards Demystified: The What, Who and Why of Your Responsibilities as a Director
Wilson Sonsini is proud to partner with MedTech Women.
Affiliated Programs
Frontiers of Neuro
Wilson Sonsini is excited to sponsor an afternoon of networking and breakthrough presentations on the frontier of neuroscience, hosted by PsyMed Ventures and E11 Bio.
Affiliated Programs
Power of Single-Cell-Multi-Omics: From Bench to Bedside
Wilson Sonsini is pleased to support EPPIC Global.
Affiliated Programs
Yokohama LINK-J Life Science Lounge NYC Meetup 2026: Bridging the U.S. and Japan Life Science Ecosystems
Wilson Sonsini is pleased to host the Yokohama LINK-J Life Science Lounge NYC Meetup 2026 – Bridging the U.S. and Japan Life Science Ecosystems. The Yokohama LINK-J Life Science Lounge is a hub established in New York through the collaboration between the City of Yokohama Representative Office to the Americas and LINK-J, with the aim of strengthening connections and fostering collaboration in the life science sector between the United States and Japan. The Lounge serves both as an information platform providing insights into the U.S. life science and business landscape, and as a networking hub that connects companies, research institutions, and industry experts, thereby promoting cross-border ecosystem collaboration and open innovation.
Affiliated Programs
CBSA Thought Leadership Series: Intellectual Property
Wilson Sonsini is proud to sponsor the Colorado Bioscience Thought Leadership Series, a forum dedicated to exploring the critical strategic issues facing today’s life sciences companies.
Affiliated Programs
MassBio Drive Fall 2026
Wilson Sonsini is proud to partner with MassBio to help empower the next generation of tech bio innovators through Drive. This accelerator equips early-stage companies with the business curriculum, mentorship, and industry connections needed to help breakthrough science move faster and further. 
View All
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Matthew A. Argenti
Partner
Palo Alto
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
  • Litigation
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Lance E. Brady
Partner
Palo Alto
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
  • Corporate
View Profile
Jason Breen
Partner
Los Angeles
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
  • Mergers & Acquisitions
View Profile
Matthew Bresnahan
Partner
San Diego
Matt is primary outside IP counsel to more than 50 life sciences companies in Southern California.
  • Patents and Innovations
View Profile
View All
People
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Matthew A. Argenti
Partner
Palo Alto
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
  • Litigation
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
Megan J. Baier
Partner
New York
Megan represents technology and life sciences clients in corporate transactional matters.
  • Corporate
View Profile
Mark B. Baudler
Partner
Palo Alto
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Lance E. Brady
Partner
Palo Alto
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
  • Corporate
View Profile
Jason Breen
Partner
Los Angeles
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
  • Mergers & Acquisitions
View Profile
Matthew Bresnahan
Partner
San Diego
Matt is primary outside IP counsel to more than 50 life sciences companies in Southern California.
  • Patents and Innovations
View Profile
View All
Related Practices
  • Corporate Life Sciences
  • FDA Regulatory, Healthcare, and Consumer Products
  • Patents and Innovations
  • Technology Transactions
  • Life Sciences Business Advisory Practice
  • Litigation
Related Industries
  • AI in Healthcare
  • Animal Health
  • Biotech
  • Digital Health
  • Global Generics
  • Medical Devices
Recent Insights
Client Highlights
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Learn More
View All
Recent Events
Affiliated Programs
MedtechASCEND Boardroom Pathways, Boards Demystified: The What, Who and Why of Your Responsibilities as a Director
Wilson Sonsini is proud to partner with MedTech Women.
Learn More
Affiliated Programs
Frontiers of Neuro
Wilson Sonsini is excited to sponsor an afternoon of networking and breakthrough presentations on the frontier of neuroscience, hosted by PsyMed Ventures and E11 Bio.
Learn More
View All
Newsletters
2024 Mid-Year Technology and Life Sciences PIPE and RDO Report
Wilson Sonsini Goodrich & Rosati is pleased to present the 2024 Mid-Year Technology and Life Sciences PIPE and RDO Report, analyzing 124 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based tech and life science companies between January 1 and June 30, 2024.
Read the Report
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.